10 results about "Rhodopsin" patented technology

The invention relates to the technical field of biomedicine, discloses mutant photo-induced ion channel ChR-2 protein, and further discloses a nucleic acid construct, an expression vector, a cell, related application and a computer model. The light-sensitive channel ChR2 protein mutant obtained by the invention has stronger light current, and the light-sensitive capability of the light-sensitive channel ChR2 protein mutant is at least improved by 100 times; besides, the invention also obtains a nucleotide sequence for coding the light-sensitive channel ChR2 protein mutant, constructs a recombinant expression vector, and obtains the light-sensitive channel ChR2 protein with higher expression quantity and stronger light sensitivity, and the light-sensitive channel ChR2 protein is very suitable for expression in cells of mammals (especially human); according to the invention, the rhodopsin in different channels is systematically studied by modifying the position G224 in the helix 6 of seven transmembrane helix motifs, which proves that the mutation of the position G224 in the helix 6 in WT ChR2 accelerates the photosensitivity of the channels, and the considered position is homologous in the helix 6 of the rhodopsin in different channels.

The disclosure relates to a fusion protein including a transcription enhancer and a dCas9 protein, a complex for epigenetic regulation including the fusion protein and one or more guide RNAs (gRNAs), etc.The fusion protein or complex according to an aspect may induce apoptosis of colorectal cancer cells or compensate for rhodopsin deficiency by activating the gene EGFL8, opsin mw, etc., and may be utilized as a pharmaceutical composition or the like for preventing or treating cancer or ocular diseases.

Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

The invention discloses a visual purple protein maximum absorption light wavelength prediction method based on a graph neural network. Comprising the following steps: generating a three-dimensional structure model according to an amino acid sequence of a to-be-predicted rhodopsin protein; generating a ligand pocket graph according to the three-dimensional structure model of the visual purple protein to be predicted; and inputting the ligand pocket graph into a pre-trained maximum absorption wavelength prediction model to obtain a maximum absorption wavelength prediction value. The method can make full use of protein three-dimensional structure information, accurately characterizes the ligand binding pocket microenvironment, has high prediction precision and strong generalization ability, and has important scientific significance and application value.

The present disclosure provides systems, methods, and compositions for modifying a target nucleic acid. Particularly, the present invention relates to modifying sequences in the 5' UTR near the Kozak sequence to silence a gene, for example, mutating a target rhodopsin allele start codon or deleting a region of the target rhodopsin allele comprising at least a portion of the start codon.

A quantum dot (QD)-rhodopsin bioconjugate system uses Förster resonance energy transfer (FRET)-mediated induction of cellular membrane depolarization via optical activation of ion channel proteins channelrhodopsin (ChR).

Described herein are pharmacologic correctors of rhodopsin, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating disease.

Described herein are pharmacologic correctors of rhodopsin, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating disease.

Provided are a chimeric protein of two types of rhodopsins, an ion-transporting rhodopsin and a G protein-coupled receptor rhodopsin, and a nucleic acid encoding the same, for the prevention and suppression of progression of retinal diseases, the improvement in visual cognitive behavioral functions (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and / or crisis avoidance functions), and the enhancement of visual functions (e.g., improvement in visual acuity). The present invention also provides a method for preventing or suppressing the progression of a disease, disorder or symptom of the retina, for improving a visual cognitive behavioral function (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and / or crisis avoidance functions), or for enhancing visual functions (e.g., improvement in visual acuity), in a subject, where the method comprises the step of administering an effective amount of a nucleic acid encoding a chimeric protein of an ion-transporting receptor rhodopsin and a G protein-coupled receptor rhodopsin to the subject.

A method of treating a retinal disease in a subject in need thereof, the method comprising administering to the subject a vector that comprises a mirtron for knocking down expression of a target gene expressed in the retina and a gene therapy vector comprising a mirtron for rhodopsin knock-down.